PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
Sign Up to like & getrecommendations! Published in 2022 at "Vascular Health and Risk Management"
DOI: 10.2147/vhrm.s275739
Abstract: Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing… read more here.
Keywords: pcsk9 inhibitors; pcsk9; management cardiovascular; risk ... See more keywords